Francis Medical Reports First Midwest Commercial Use of Vanquish Prostate Ablation System

According to a recent LinkedIn post from Francis Medical, the company is highlighting what it describes as the first commercial, non‑clinical trial procedure in the U.S. Midwest using its Vanquish Water Vapor Ablation System. The procedure was reportedly performed at High Pointe Surgery Center in Lake Elmo, Minnesota, by Dr. Aaron Milbank of Minnesota Urology, and is characterized as the system’s first use in routine clinical practice in that region.

The post explains that the Vanquish system, developed by Francis Medical, is designed to ablate targeted prostate tissue via high‑energy sterile water vapor delivered through a transurethral approach. It also notes that the technology is FDA‑cleared and restricted to prescription use, with further safety information available on the company’s website.

For investors, the described transition from clinical trials to initial commercial use in a new geographic market may indicate early momentum in market adoption and the beginning of revenue‑generating procedures. If similar commercial uptake extends beyond this site and across additional urology practices, Francis Medical could be positioned to strengthen its competitive standing in the minimally invasive prostate treatment segment.

The recognition of Minnesota Urology and High Pointe Surgery Center in the post suggests targeted engagement with key opinion leaders and outpatient surgery centers, which could be important channels for broader rollout. Consistent execution of this strategy, coupled with demonstrated clinical outcomes and reimbursement support, would be central to scaling utilization and enhancing the company’s long‑term growth prospects.